Katalog der Deutschen Nationalbibliothek

Go to:

Catalogue (Beta)

Knowledge Web

Person
Person

Person

Marcus Schmidt

Gynäkologe

Name

Marcus Schmidt

Place

Mainz (Wirkungsort)
Deutschland

Gender

männlich

Academic degree

Dr. med.

Profession

Gynäkologe (characteristic profession)
Onkologe

Variant

M. Schmidt

Further information

Diss. Humanmedizin an der Universität Mainz (1995); Habil.-Schr. Medizin (Klinik und Poliklinik für Geburtshilfe und Frauenheilkunde) an der Universität Mainz (2010)

Record type

Person

GND-Identifier

1016470517

Record ID

1016470517

Involved in

show all

Prognostic impact of metabolic syndrome in patients with primary endometrial cancer: a retrospective bicentric study

Antikörper-Wirkstoff-Konjugate beim metastasierten Mammakarzinom : Eine vielversprechende Behandlungsstrategie

Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study

Chemotherapy in older patients with early breast cancer

Personalisierte Medizin – von der Translation zur Klinik

Progesterone from ovulatory menstrual cycles is an important cause of breast cancer

PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

Personalisierte Medizin – von der Translation zur Klinik

A questionnaire-based survey on the diagnostic and therapeutic approaches for patients with STIC in Germany

Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

Prognostische Faktoren bei Patientinnen mit Mammakarzinom und leptomeningealen Metastasen: eine Subanalyse des deutschen Registers für Hirnmetastasen beim Mammakarzinom – Versorgungsforschungspreis der DGS 2023 – eine Kurzübersicht

AGO-Empfehlungen zur operativen Therapie des Mammakarzinoms: Update 2022

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare

Anti-tumor effects of low-dose metronomic vinorelbine in combination with alpelisib in breast cancer cells

Which Patients Need Chemotherapy? From Pathological Risk Factors to Gene Signatures and Evaluation of Endocrine Response

Breast Cancer Outcome: What Have We Achieved

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2023

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2023

Real-World Experience of Metronomic Chemotherapy in Metastatic Breast Cancer: Results of a Retrospective Unicenter Study

AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2023

Arbeitsgemeinschaft Gynäkologische Onkologie Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer : Update 2023

Arbeitsgemeinschaft Gynäkologische Onkologie recommendations for the diagnosis and treatment of patients with early breast cancer: update 2023

Elacestrant : erster oraler SERD speziell für die Therapie von lokal fortgeschrittenem oder metastasiertem ER+/HER2-Brustkrebs mit ESR1-Mutationen

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer – controversies and standards in healthcare

Systemic therapy of premenopausal patients with early stage hormone receptor-positive, HER2-negative breast cancer: controversies and standards in healthcare

Vakzinierungsstrategien beim Mammakarzinom

Influence of interdisciplinary frailty screening on perioperative complication rates in elderly ovarian cancer patients: results of a retrospective observational study

Frailty assessment tools predict perioperative outcome in elderly patients with endometrial cancer better than age or BMI alone: a retrospective observational cohort study

Comparison of cisplatin and mitomycin C/5-FU as radiosensitisers in the treatment of locally advanced vulvar cancer: results of a retrospective, observational, single-institutional cohort study

The preoperative G8 geriatric screening tool independently predicts survival in older patients with endometrial cancer: results of a retrospective single-institution cohort study

AGO-Empfehlungen zur operativen Therapie der Axilla nach neoadjuvanter Chemotherapie: Update 2021

Metronomic Chemotherapy for Metastatic Breast Cancer

New Opportunities in Advanced Breast Cancer

G-8 Geriatric Screening Tool Independently Predicts Progression-Free Survival in Older Ovarian Cancer Patients Irrespective of Maximal Surgical Effort: Results of a Retrospective Cohort Study

AGO Recommendations for the Surgical Therapy of Breast Cancer: Update 2022

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2022

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022

Ago recommendations for the surgical therapy of breast cancer: update 2022

AGO Recommendations for the surgical therapy of breast cancer: update 2022

Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients : a retrospective cohort study in Germany (ESCaRa)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer

Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference : Substudy of the randomised phase III GAIN-2 study

Role of integrins in the metastatic spread of high-grade serous ovarian cancer

Cardiac late effects after modern 3D-conformal radiotherapy in breast cancer patients: a retrospective cohort study in Germany (ESCaRa)

Erratum zu: Zielgerichtete Therapie beim metastasierten Mammakarzinom – welche molekularen Tests sind notwendig?

Update Immunonkologie beim triple-negativen Mammakarzinom

Agnostische Tumortherapie – was ist das?

Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046

Any progress in informed consenting for cancer treatment? Results from a cross sectional analysis at a comprehensive cancer center

AGO-Algorithmen zur Behandlung von Brustkrebs: Update 2021

Correction: AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update

AGO Algorithms for the Treatment of Breast Cancer: Update 2021

Prognostic Impact of Immunoglobulin Kappa C in Breast Cancer Patients Treated with Adjuvant Chemotherapy

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021

AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021

AGO Algorithms for the Treatment of Breast Cancer: Update 2021

AGO Recommendations for the diagnosis and treatment of patients with early breast cancer: update 2021

AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer : update 2021

AGO recommendations for the surgical therapy of the axilla after neoadjuvant chemotherapy: 2021 Update
Please note

The beta version does not yet contain all functions and information of the DNB portal catalogue. If you are missing information or want to order a medium, please visit the page in the DNB portal catalogue via the following link:

DNB portal